Skip to main content
Quest Diagnostics

Genetic Results in a Cohort of 633 Patients With Optic Atrophy

ARVO 2024

The Association for Research in Vision and Ophtamology

Seattle, WA, May 5-9, 2024

Poster presentation: Genetic Results in a Cohort of 633 Patients With Optic Atrophy

Author: Tuupanen S, Gall K, Hathaway J, Vattulainen-Collanus S, Merkkiniemi K, Kämpjärvi K, von Nandelstadh P, Kurtz LC, Bai S, Muona M, Pietilä T, Salmenperä P, Saarinen I, Veeraraghavan R, Myllykangas S, Koskenvuo J

Specialty: Genetics, Ophtamology

Disclaimer: One or more of the authors of this abstract were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

Publication
Late-onset autosomal dominant macular degeneration caused by deletion of the CRX gene
Conference Presentation
Next-Generation Sequencing Panel Results for Inherited Retinal Dystrophy in a Large Pediatric Cohort
Conference Presentation
Diagnostic Contribution of Genes with Treatments or Interventional Clinical Trials in a Large Retinal Dystrophy Cohort

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.